Atara Biotherapeutics, Inc. ATRA
Set alert
8.48 USD +0.47 +5.87%
At close · Nov 2
8.48 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
8.02 Day range 8.59
3.92 52-week range 19.15
- YTD
- -53.12%
- 1 year
- -42.90%
- Open
- 8.05
- Prev close
- 8.01
- Mkt cap
- 85.12M
- Vol
- 32.05K
- Avg vol
- 41.51K
- EPS
- -1.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.02
- High
- 8.59
- Forward P/E
- -1.52
- Beta
- 0.49
- Short ratio
- 7.11
- Inst. own
- 50.82%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.80
- 200-d avg
- 11.70
- 1y target
- 16.33
1m chart
Built from the cached one-day intraday bars.
Signals (6)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 4:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:53 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:19 PM | 3 days ago |
| RSI: Oversold | Oct 30, 3:19 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:34 PM | 3 days ago |
Analyst view
Consensus: buy
Buy
Price target (mean) 16.33 +92.6% upside
Now 8.48
- Target (low)
- 10.00
- Target (mean)
- 16.33
- Target (high)
- 21.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -2.34 | -2.49 – -2.18 | -14.00 | +83.3% | 33.09M | +678.3% | 2 |
| Next quarter | -0.16 | -3.37 – 3.05 | -5.75 | +97.2% | 37.35M | +36.5% | 2 |
| Current year | -1.52 | -2.23 – -0.80 | -65.25 | +97.7% | 129.19M | +1406.9% | 2 |
| Next year | -11.96 | -20.49 – -0.97 | -1.52 | -689.6% | 84.82M | -34.3% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Rodman & Renshaw | Initiated | — | Buy |
| Nov 13, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Aug 16, 2024 | Mizuho | Upgrade | Neutral | Outperform |
| Aug 13, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 17, 2024 | Goldman Sachs | Maintained | Sell | Sell |
| May 22, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Apr 1, 2024 | Stifel | Maintained | Hold | Hold |
| Nov 10, 2023 | Goldman Sachs | Maintained | Sell | Sell |
| Nov 9, 2023 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Nov 9, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Nov 9, 2023 | Mizuho | Downgrade | Buy | Neutral |
| Sep 26, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 21, 2023 | Citigroup | Maintained | Sell | Sell |
| Aug 9, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Jun 14, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 9, 2023 | Canaccord Genuity | Maintained | — | Buy |
| Feb 9, 2023 | EF Hutton | Reiterated | — | Buy |
| Feb 9, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 7, 2023 | Mizuho | Reiterated | — | Buy |
| Jan 5, 2023 | EF Hutton | Initiated | — | Buy |
| Aug 16, 2022 | Mizuho | Maintained | — | Buy |
| Aug 9, 2022 | Goldman Sachs | Maintained | — | Sell |
| Jul 20, 2022 | Citigroup | Downgrade | Neutral | Sell |
| Jul 13, 2022 | JP Morgan | Downgrade | Overweight | Neutral |
| Jul 13, 2022 | Stifel | Downgrade | Buy | Hold |
| May 24, 2022 | Goldman Sachs | Maintained | — | Sell |
| May 23, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 10, 2022 | Citigroup | Downgrade | Buy | Neutral |
| Mar 28, 2022 | JP Morgan | Maintained | — | Overweight |